Critical evaluation of the efficacy and tolerability of azilsartan

References

• RosendorffCBlackHRCannonCPTreatment of hypertension in the prevention and management of ischemic heart disease: a scientific statement from the American Heart Association Council for High Blood Pressure Research and the Councils on Clinical Cardiology and Epidemiology and PreventionCirculation2007115212761278817502569
   PubMed Web of Science ®Google Scholar
• YusufSReddySOunpuuSAnandSGlobal burden of cardiovascular diseases: part I: general considerations, the epidemiologic transition, risk factors, and impact of urbanizationCirculation2001104222746275311723030
   PubMed Web of Science ®Google Scholar
• KearneyPMWheltonMReynoldsKMuntnerPWheltonPKHeJGlobal burden of hypertension: analysis of worldwide dataLancet2005365945521722315652604
   PubMed Web of Science ®Google Scholar
• GuilbertJJThe world health report 2002 – reducing risks, promoting healthy lifeEduc Health (Abingdon)200316223014741909
   PubMedGoogle Scholar
• LawesCMVander HoornSRodgersAInternational Society of Hypertension. Global burden of blood-pressure-related disease, 2001Lancet200837196231513151818456100
   PubMed Web of Science ®Google Scholar
• LawesCMVander HoornSLawMRElliottPMacMahonSRodgersABlood pressure and the global burden of disease 2000. Part II: estimates of attributable burdenJ Hypertens200624342343016467640
   PubMed Web of Science ®Google Scholar
• ManciaGDe BackerGDominiczakA2007ESH-ESC Practice Guidelines for the Management of Arterial Hypertension: ESH-ESC Task Force on the Management of Arterial HypertensionJ Hypertens20072591751176217762635
   PubMed Web of Science ®Google Scholar
• PittBSegalRMartinezFARandomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE)Lancet199734990547477529074572
   PubMed Web of Science ®Google Scholar
• LewisEJHunsickerLGClarkeWRRenoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetesN Engl J Med20013451285186011565517
   PubMed Web of Science ®Google Scholar
• BrennerBMCooperMEde ZeeuwDEffects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathyN Engl J Med20013451286186911565518
   PubMed Web of Science ®Google Scholar
• McMurrayJSolomonSPieperKThe effect of valsartan, captopril, or both on atherosclerotic events after acute myocardial infarction: an analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT)J Am Coll of Cardiol200647472673316487836
   PubMed Web of Science ®Google Scholar
• PfefferMASwedbergKGrangerCBEffects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programmeLancet2003362938675976613678868
   PubMed Web of Science ®Google Scholar
• EhretGBMunroePBRiceKMGenetic variants in novel pathways influence blood pressure and cardiovascular disease riskNature2011478736710310910.1038/nature10405.21909115
   PubMed Web of Science ®Google Scholar
• ZamanMAOparilSCalhounDADrugs targeting the renin-angiotensinaldosterone systemNat Rev Drug Discov20021862163612402502
   PubMed Web of Science ®Google Scholar
• HeranBSWongMMHeranIKWrightJMBlood pressure lowering efficacy of angiotensin converting enzyme (ACE) inhibitors for primary hypertensionCochrane Database Syst Rev20084CD00382318843651
   PubMed Web of Science ®Google Scholar
• McManusRJCaulfieldMWilliamsBNational Institute for Health and Clinical ExcellenceNICE hypertension guideline 2011: evidence based evolutionBMJ2012344e18110.1136/bmj.e181.22246269
   PubMed Web of Science ®Google Scholar
• MaronBALeopoldJAAldosterone receptor antagonists: effective but often forgottenCirculation2010121793493920177008
   PubMed Web of Science ®Google Scholar
• MusiniVMFortinPMBassettKWrightJMBlood pressure lowering efficacy of renin inhibitors for primary hypertension: a Cochrane systematic reviewJ Hum Hypertens200923849550219158826
   PubMed Web of Science ®Google Scholar
• CuculiFErnePCombined neutral endopeptidase inhibitorsExpert Opin on Investig Drugs2011204457463
   PubMed Web of Science ®Google Scholar
• KurtzTWKajiyaTDifferential pharmacology and benefit/risk of azilsartan compared to other sartansVasc Health Risk Manag2012813314322399858
   PubMedGoogle Scholar
• JonesJDJacksonSHAgbotonCMartinTSAzilsartan medoxomil (Edarbi): the eighth angiotensin II receptor blockerPT20113610634640
   PubMedGoogle Scholar
• RakugiHEnyaKSugiuraKIkedaYComparison of the efficacy and safety of azilsartan with that of candesartan cilexetil in Japanese patients with grade I–II essential hypertension: a randomized, double-blind clinical studyHypertens Res201210.1038/hr.2012.8.
   Web of Science ®Google Scholar
• ZaikenKChengJWAzilsartan medoxomil: a new angiotensin receptor blockerClin Ther201133111577158922071238
   PubMed Web of Science ®Google Scholar
• KajiyaTHoCWangJVilardiRKurtzTWMolecular and cellular effects of azilsartan: a new generation angiotensin II receptor blockerJ Hypertens201129122476248321986624
   PubMed Web of Science ®Google Scholar
• Center for Drug Evaluation and Research [website on the Internet]. Silver Spring, MD: NDA 200-796: Azilsartan medoxomil, Clinical Pharmacology and Biopharmaceutics Review(s)2010 Available from: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/200796Orig1s000ClinPharmR.pdfAccessed 1 April, 2012
   Google Scholar
• Edarbi.com [homepage on the Internet]Two options to help lower blood pressureDeerfield, ILTakeda Pharmaceuticals America, Inc2012 Available from: http://www.edarbi.com/Accessed 1 April, 2012
   Google Scholar
• OjimaMIgataHTanakaMIn vitro antagonistic properties of a new angiotensin type 1 receptor blocker, azilsartan, in receptor binding and function studiesJ Pharmacol Exp Ther2011336380180821123673
   PubMed Web of Science ®Google Scholar
• FrenchCJZamanAKSobelBEThe angiotensin receptor blocker, azilsartan medoxomil (TAK-491), suppresses vascular wall expression of plasminogen activator inhibitor type-I protein potentially facilitating the stabilization of atherosclerotic plaquesJ Cardiovasc Pharmacol201158214314821558880
   PubMed Web of Science ®Google Scholar
• GrassiGSeravalleGDell’OroRComparative effects of candesartan and hydrochlorothiazide on blood pressure, insulin sensitivity, and sympathetic drive in obese hypertensive individuals: results of the CROSS studyJ Hypertens20032191761176912923410
   PubMed Web of Science ®Google Scholar
• KusumotoKIgataHOjimaMAntihypertensive, insulin-sensitising and renoprotective effects of a novel, potent and long-acting angiotensin II type 1 receptor blocker, azilsartan medoxomil, in rat and dog modelsEur J Pharmacol20116691–3849321816148
   PubMed Web of Science ®Google Scholar
• ZhaoMLiYWangJAzilsartan treatment improves insulin sensitivity in obese spontaneously hypertensive Koletsky ratsDiabetes Obes Metab2011131211231129 10.1111/j.1463-1326.2011.01471.x21749604
   PubMed Web of Science ®Google Scholar
• ThomasGSehgalARKashyapSRSrinivasTRKirwanJPNavaneethanSDMetabolic syndrome and kidney disease: a systematic review and meta-analysisClin J Am Soc Nephrol20116102364237321852664
   PubMed Web of Science ®Google Scholar
• SeguraJCampoCGilPRoldánCDevelopment of chronic kidney disease and cardiovascular prognosis in essential hypertensive patientsJ Am Soc Nephrol20041561616162215153573
   PubMed Web of Science ®Google Scholar
• BakrisGLSicaDWeberMThe comparative effects of azilsartan medoxomil and olmesartan on ambulatory and clinic blood pressureJ Clin Hypertens (Greenwich)20111328188 10.1111/j.1751-7176.2010.00425.x21272195
   PubMed Web of Science ®Google Scholar
• SicaDWhiteWBWeberMAComparison of the novel angiotensin II receptor blocker azilsartan medoxomil vs valsartan by ambulatory blood pressure monitoringJ Clin Hypertens (Greenwich)201113746747210.1111/j.1751-7176.2011.00482.x.21762358
   PubMed Web of Science ®Google Scholar